Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CSF2 [8] JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Rheumatoid arthritis D11343 Otilimab [2] 46, 256
2 CSF2RA [2] JAK-STAT signaling pathway, Pathways in cancer D05066 Molgramostim [3] 97, 229, 299
3 CSF2RA [2] JAK-STAT signaling pathway, Pathways in cancer D05712 Regramostim [1] 229
4 CSF2RA [2] JAK-STAT signaling pathway, Pathways in cancer D05803 Sargramostim [7] 6, 28, 60, 62, 96, 229, 285
5 CSF2RA [2] JAK-STAT signaling pathway, Pathways in cancer D09930 Mavrilimumab [2] 41, 46
6 CSF3R [3] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D03235 Filgrastim [34] 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
7 CSF3R [3] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D03247 Lenograstim [7] 2, 13, 16, 18, 19, 57, 65
8 CSF3R [3] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D06889 Pegfilgrastim [1] 60
9 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01977 Gefitinib [1] 75
10 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D03455 Cetuximab [5] 34, 51, 86, 89, 331
11 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D04023 Erlotinib [1] 94
12 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D04024 Lapatinib [3] 34, 74, 75
13 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D07907 Erlotinib [1] 94
14 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08108 Lapatinib [3] 34, 74, 75
15 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11251 Icotinib [1] 34
16 EGFR [19] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11772 Tesevatinib [1] 67
17 EPOR [3] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D03231 Erythropoietin [10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
18 EPOR [3] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D09946 Peginesatide [1] 283
19 MTOR [21] Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00753 Sirolimus [41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
20 MTOR [21] Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D02714 Everolimus [9] 34, 67, 89, 96, 137, 157, 158, 228, 277
21 MTOR [21] Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06068 Temsirolimus [4] 13, 34, 89, 331
22 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D02691 Somatotropin [23] 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
23 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D03297 Mecasermin [6] 65, 78, 96, 168, 265, 299
24 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D04870 Mecasermin [6] 65, 78, 96, 168, 265, 299
25 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D05394 Pegvisomant [1] 78
26 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11193 Somavaratan [1] 78
27 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11194 Somapacitan [1] 78
28 GHR [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11486 Lonapegsomatropin [1] 78
29 IFNA1 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
30 IFNA1 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
31 IFNA2 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
32 IFNA2 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
33 IFNA4 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
34 IFNA4 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
35 IFNA5 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
36 IFNA5 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
37 IFNA6 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
38 IFNA6 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
39 IFNA7 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
40 IFNA7 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
41 IFNA8 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
42 IFNA8 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
43 IFNA10 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
44 IFNA10 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
45 IFNA13 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
46 IFNA13 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
47 IFNA14 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
48 IFNA14 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
49 IFNA16 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
50 IFNA16 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
51 IFNA17 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
52 IFNA17 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
53 IFNA21 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab [1] 49
54 IFNA21 [12] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab [1] 49
55 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00745 Interferon alfa-2a [1] 56
56 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00746 Interferon beta-1b [1] 13
57 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
58 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
59 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
60 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
61 IFNAR1 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D11082 Anifrolumab [2] 46, 49
62 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00745 Interferon alfa-2a [1] 56
63 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00746 Interferon beta-1b [1] 13
64 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
65 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
66 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
67 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
68 IFNAR2 [10] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D11082 Anifrolumab [2] 46, 49
69 IFNG [18] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04242 Fontolizumab [1] 46
70 IFNG [18] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D11120 Emapalumab [2] 49, 107
71 IFNGR1 [12] Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
72 IFNGR2 [11] Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
73 IL2RA [7] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
74 IL2RA [7] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03058 Basiliximab [6] 2, 50, 66, 97, 222, 228
75 IL2RA [7] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03639 Daclizumab [8] 13, 56, 60, 65, 97, 107, 283, 284
76 IL2RB [8] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Transcriptional misregulation in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
77 IL2RG [8] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Primary immunodeficiency D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
78 IL4 [7] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Leishmaniasis, Pathways in cancer D03117 Binetrakin [1] 46
79 IL4R [5] PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer D10354 Dupilumab [4] 51, 98, 160, 162
80 IL5 [4] JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer D04923 Mepolizumab [4] 44, 45, 98, 162
81 IL5 [4] JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer D08985 Reslizumab [2] 44, 98
82 IL5RA [2] JAK-STAT signaling pathway, Pathways in cancer D09874 Benralizumab [5] 44, 45, 98, 162, 299
83 IL6 [23] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
84 IL6 [23] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
85 IL6 [23] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D09669 Siltuximab [2] 28, 331
86 IL6 [23] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D10080 Sirukumab [2] 41, 46
87 IL6R [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D02596 Tocilizumab [21] 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
88 IL6R [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D10161 Sarilumab [5] 41, 46, 84, 107, 271
89 IL6R [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D11079 Satralizumab [2] 11, 13
90 IL10 [11] Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway, T cell receptor signaling pathway, Pertussis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
91 IL11RA [1] JAK-STAT signaling pathway D05266 Oprelvekin [2] 96, 288
92 IL12A [14] Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
93 IL12B [14] Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
94 IL13 [3] JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D08857 Anrukinzumab [1] 97
95 IL13 [3] JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D09633 Lebrikizumab [1] 85
96 IL13 [3] JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D09979 Tralokinumab [2] 85, 97
97 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib [1] 228
98 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
99 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib [13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
100 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib [1] 46
101 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib [6] 46, 53, 96, 97, 222, 271
102 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib [5] 46, 51, 60, 97, 228
103 JAK1 [17] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib [8] 40, 41, 46, 49, 96, 97, 107, 271
104 JAK2 [14] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09959 Ruxolitinib [1] 228
105 JAK2 [14] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
106 JAK2 [14] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10308 Baricitinib [13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
107 JAK2 [14] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10653 Peficitinib [1] 46
108 JAK3 [11] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
109 JAK3 [11] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib [1] 46
110 LEPR [3] Neuroactive ligand-receptor interaction, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease D05014 Metreleptin [1] 265
111 MPL [1] JAK-STAT signaling pathway D08990 Romiplostim [4] 60, 63, 64, 65
112 MPL [1] JAK-STAT signaling pathway D10306 Avatrombopag [2] 60, 63
113 IL20 [2] Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway D11756 Fletikumab [1] 46
114 IL22 [2] JAK-STAT signaling pathway, Th17 cell differentiation D11953 Efmarodocokin alfa [2] 96, 97
115 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D09214 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
116 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10400 Tildrakizumab [2] 162, 271
117 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10438 Guselkumab [5] 37, 41, 51, 96, 97
118 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10912 Brazikumab [2] 96, 97
119 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D11052 Risankizumab [4] 37, 96, 97, 271
120 IL23A [6] JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D11123 Mirikizumab [3] 37, 96, 97
121 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D01441 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
122 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D06402 Sunitinib [2] 28, 34
123 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08066 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
124 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08552 Sunitinib [2] 28, 34
125 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08953 Nilotinib [5] 6, 8, 34, 51, 86
126 PDGFRA [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D10481 Nintedanib [5] 51, 85, 89, 227, 228
127 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D03658 Dasatinib [2] 51, 85
128 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D06272 Sorafenib [2] 34, 86
129 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D06402 Sunitinib [2] 28, 34
130 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D06414 Dasatinib [2] 51, 85
131 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08524 Sorafenib [2] 34, 86
132 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08552 Sunitinib [2] 28, 34
133 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08953 Nilotinib [5] 6, 8, 34, 51, 86
134 PDGFRB [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D10481 Nintedanib [5] 51, 85, 89, 227, 228
135 PIK3CA [50] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib [2] 53, 65
136 PIK3CB [50] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib [2] 53, 65
137 PIK3CD [50] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib [2] 53, 65
138 PIK3CD [50] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11437 Parsaclisib [3] 35, 53, 61
139 PRL [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00780 Bromocriptine [2] 6, 74
140 PRL [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
141 PRL [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D01348 Terguride [2] 51, 86
142 PRL [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
143 RAF1 [39] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06272 Sorafenib [2] 34, 86
144 RAF1 [39] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib [2] 34, 86
145 BCL2 [22] Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer, Lipid and atherosclerosis D10679 Venetoclax [1] 28
146 TYK2 [9] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
147 TYK2 [9] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection D11817 Deucravacitinib [2] 96, 97